Violet Therapeutics
Preclinical biotech developing first-in-class CNS therapies via the CONNECT platform, targeting EphB3 for neurodegenerative diseases.
Founded
2021Preclinical biotech developing first-in-class CNS therapies via the CONNECT platform, targeting EphB3 for neurodegenerative diseases.
Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative diseases by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company's proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.
The company's lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase that mediates microglia-astrocyte interactions driving glial dysfunction in neurodegenerative disease. Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer's disease and other neurodegenerative conditions, and Violet's lead program is designed to address this core pathology through glial-mediated synaptic preservation and repair.
Companies similar to Violet Therapeutics include Allyx Therapeutics, Spinogenix, Ilios and Souvien Therapeutics.
Violet Therapeutics was founded in 2021.
Violet Therapeutics' headquarters is located in Norwalk, CT, US.
Violet Therapeutics' most recent funding round was for $10.6M (USD) in May 2023.
As of May 5, 2023, Violet Therapeutics has disclosed funding of $15.3M (USD). Undisclosed round amounts are excluded.
Violet Therapeutics has 6 employees as of Feb 5, 2024.
Souvien Therapeutics
